Ovarian hyperstimulation syndrome(OHSS)stands as a significant complication within assisted reproductive technology.Currently,clinical strategies to prevent OHSS encompass mild ovarian stimulation,coasting therapy,etc.,but it cannot be completely avoided.Recent investigations suggest that letrozole may mitigate early-onset OHSS by reducing serum estradiol levels or potentially suppressing vascular endothelial growth factor expression.Although letrozole has shown potential in preventing OHSS,its effectiveness remains controversial,and extensive prospective randomized controlled trials are needed to clarify its effects.This study provides an overview of the evolving research on letrozole's role in OHSS prevention,aiming to offer guidance and insights for clinical practice.
维普
万方数据